Two emerging MRI techniques show promise as all-in-one imaging tests for patients with pain in and below the lower back due to changes in the sacroiliac joint.

A clinical trial pitting MRI against a burgeoning PET/CT technique has found the de facto defending champion better at revealing the presence of any grade of prostate cancer.

Editor David Bluemke, MD, PhD, says the journal’s rising impact factor is “representative of the fundamental importance of imaging throughout our hospitals and clinics.”

The FDA has cleared a focused-ultrasound developer to compare the safety and efficacy of acoustic energy for treating prostate cancer against the more conservative approach of active surveillance.

One of the largest private health insurers in the U.S. has gone from considering hybrid PET/CT for cardiac indications “experimental/investigational” to displaying willingness to pay for the modality. 

In the June 29 announcement, the ACR revealed CMS said the additional evidence provided to them was “insufficient” to support the reconsideration of their non-coverage decision.

Patients who received an injection had an infection rate of 2.2% at 4-month follow-up. In comparison, the infection rate for the general population in Massachusetts was 7.5% during the same period.

COVID-19 was the third leading cause of death in the U.S. in both 2020 and 2021, according to the National Institutes of Health.